Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ALTO-100
ALTO-100
Alto Neuroscience’s depression drug trial fails at phase 2
Biopharma Reporter
Thu, 10/24/24 - 10:50 am
Alto Neuroscience
clinical trials
clinical depression
ALTO-100
Alto’s midphase depression trial falls flat, raising doubts about pitch to disrupt neuropsychiatry R&D
Fierce Biotech
Wed, 10/23/24 - 11:38 am
Alto Neuroscience
clinical trials
ALTO-100
major depressive disorder
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety